Bruker Corp - BRKR STOCK NEWS

Bruker (Nasdaq: BRKR) announced the launch of Beacon Discovery™ Optofluidic System, a new benchtop system for live single-cell functional analysis, at the AACR Annual Meeting 2025. The system features Bruker's proprietary Opto-Electrical Positioning technology and OptoSelect™ microfluidic chips.

The compact Beacon Discovery complements existing premium Beacon® platforms with a lower cost of ownership and reduced running costs. It offers precise single-cell isolation, control, and analysis capabilities using machine learning automation. The system enables multi-parameter temporal analysis over extended periods, combining live-cell imaging with sequential assays.

Targeting academic and biotech laboratories, Beacon Discovery focuses on applications in immuno-oncology, infectious diseases, autoimmune disorders, and immune profiling. Commercial shipments are expected later in 2025, with pre-orders now available.

Bruker (Nasdaq: BRKR) has launched the nVista 2P miniature two-photon microscope, expanding their Inscopix product line for neural circuit imaging in freely behaving animals. This groundbreaking 2-gram microscope enables high-resolution imaging at depths up to 300 microns with 3D data reconstruction capabilities.

The system offers single-cell resolution for detailed exploration of densely labeled brain regions like the entorhinal cortex and hypothalamus. It's compatible with both shallow and deep GRIN lens applications and cranial window preparations, maintaining the same protocols as one-photon experiments.

According to Mostafizur Rahman from Harvard University's Dulac Lab, the microscope's lightweight design and intuitive interface ensure exceptional ease of use. Kunal Ghosh, Inscopix CEO, emphasizes that nVista 2P complements Bruker's benchtop Ultima multiphoton microscope technology, offering unique 3D brain data acquisition capabilities.

Bruker (NASDAQ: BRKR) has announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of therapeutic drug monitoring (TDM) and clinical diagnostic kits. RECIPE, with over 60 employees and 2024 revenues exceeding $15 million, will continue operating under Dr. Gernot Wolfram's leadership.

The strategic collaboration enhances Bruker's capabilities in small molecule clinical diagnostic assays through RECIPE's ClinMASS® kits for EVOQ® liquid chromatography systems. The companies are also launching high-throughput, chromatography-free ClinDART® kits for EVOQ-DART TQ⁺ systems.

The new ClinDART platform offers:

• 95% reduction in solvent use
• Lower operational costs
• Increased laboratory productivity
• Flexibility to switch between LC-TQ-MS methods and novel high-throughput workflows

Bruker (BRKR) has released preliminary revenue figures for Q1 2025, projecting revenue between $795 million to $800 million, exceeding both company outlook and consensus expectations. The company reported approximately 10% year-over-year revenue growth, with low-double digit percentage growth at constant exchange rates.

The Bruker Scientific Instrument (BSI) segment showed mid-single digit percentage organic revenue growth, while the BEST segment experienced a high-teens percentage organic revenue decline. Overall non-GAAP organic revenue growth was in the low-single digit percentages.

The company will release complete Q1 2025 financial results on May 7, 2025, before market opening, followed by an earnings conference call and webcast at 8:30 a.m. Eastern Daylight Time.

Bruker has announced a majority investment in Ridom GmbH, a Next-Generation Sequencing (NGS) bioinformatics solution provider, expanding its microbiology solutions. The strategic collaboration introduces new research-use only NGS-based solutions for epidemiology and hospital-acquired infection (HAI) tracing.

The partnership combines Bruker's IR Biotyper® for rapid, cost-effective HAI outbreak detection with Ridom's SeqSphere+™ NGS bioinformatics software, which enables genomic bacterial strain differentiation and phylogenetic analysis. This creates a unique workflow integrating MALDI Biotyper®-based microbial identification with NGS-based strain determination.

Ridom, a profitable company based in Muenster, Germany, will join Bruker's global microbiology team, though financial details were not disclosed. The collaboration aims to enhance hospital hygiene testing and epidemiological studies through complementary first-line testing and selective NGS reflex testing for confirmation and phylogeny.

Bruker has announced the successful development and testing of the world's first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. The groundbreaking system features a 30.5 Tesla field strength and incorporates a novel ReBCO high-temperature superconductor insert.

The new spectrometer maintains similar physical dimensions and cryogen consumption as Bruker's 1.2 GHz magnets. Testing was conducted using five different NMR probe configurations, demonstrating increased resolution and sensitivity for both liquids and solids NMR spectra.

The technology particularly benefits spectroscopy of bio-macromolecules lacking dispersion, such as carbohydrates, glycoproteins, RNA, and intrinsically disordered proteins. In solid-state applications, the increased field strength improves the study of quadrupolar nuclei by producing narrower spectral lines.

Bruker has unveiled its innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer at the Joint ENC-ISMAR Conference 2025. The new 'Multi-Talent' configuration represents a significant advancement in permanent magnet-based FT-NMR technology.

The system's key features include:

• Capability to measure or decouple 1H and select from 15 different X-nuclei
• Support for X{1H} experiments and 1H{X} experiments
• Enables various 2D experiments and inverse 1H observation methods
• Includes gradient spectroscopy with options for adjustable sample temperature and sample changer automation
• Uses standard 5 mm NMR samples

According to Dr. Agnes Haber, Fourier 80 Product Manager, twelve systems have already been successfully installed in customer labs. The system is particularly valuable for pharmaceutical research and battery development, supporting observations of nuclei like 7Li, 23Na, and 11B for battery electrolyte formulation.

Bruker has announced the successful first customer installation of its revolutionary dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the University of California San Francisco (UCSF). The groundbreaking technology enables over 10,000x signal gains on 13C in high-field MRI and NMR systems.

The system operates at 7 Tesla and temperatures below 1.4 Kelvin, featuring Bruker's proprietary active cross-polarization technology that provides 5-10x faster polarization compared to traditional d-DNP of 13C. This advancement is particularly significant for in vivo studies of 13C-labelled metabolites, enabling real-time tracking of metabolic differences between healthy and diseased tissues in conditions like cancer.

The installation at UCSF's Hyperpolarized MRI Technology Resource Center marks a milestone in hyperpolarized MRI for preclinical research, with additional installations planned in Europe and the US. The partnership aims to validate the d-DNP technology in oncology applications.

Bruker (Nasdaq: BRKR) has launched the X4 POSEIDON™, a high-performance benchtop 3D X-ray microscope (XRM) utilizing micro-Computed Tomography technology. The system features a high-end X-ray source that delivers over 10x improvement in 3D resolution compared to similar instruments.

Key features include:

• Large field-of-view high-efficiency detector with optional high-resolution scientific CMOS detector
• 3DxSUITE software with automated protocols and multi-language support
• Low maintenance design for enhanced uptime and reduced ownership costs
• Field-upgradable options for future expansion

The X4 POSEIDON targets applications in geosciences, pharmaceutical R&D, QA/QC, composite materials, batteries, renewable energy, microelectronics, and life sciences including bone, dental, soft tissue, and biological research.